Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Read more about Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study. Read more about Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study.
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Read more about Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Read more about A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Read more about Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Read more about TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. Read more about Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.
Pubertal timing and breast density in young women: a prospective cohort study. Read more about Pubertal timing and breast density in young women: a prospective cohort study.
Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer. Read more about Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer.
Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Read more about Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
